Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Zeis, Michael Stadler, Jörg Bittenbring, Lutz Uharek, Christof Scheid, Ute Hegenbart, Anthony Ho, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger

Blood (2017) 130 (12): 1477–1480.

https://doi.org/10.1182/blood-2017-04-775841

Published: 2017

Includes: Supplemental data

Journal Articles

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Eric R Rosenbaum, MD MPH, Patrick Wuchter, MD, Michael Hundemer, MD, Petra Pavel, MD, Mathias Witzens-Harig, MD, Hartmut Goldschmidt, MD, Bart Barlogie, MD PhD, Anthony Ho, MD, Michele H. Cottler-Fox, MD

Blood (2014) 124 (21): 2458.

https://doi.org/10.1182/blood.V124.21.2458.2458

Published: 2014

Journal Articles

Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders

Jens Hillengass, MD, Judith Ritsch, Maximilian Merz, MD, Hartmut Goldschmidt, MD, Christina Kunz, PhD, Barbara Wagner-Gund, Anthony Ho, MD, Thomas M. Moehler, MD, Stefan Delorme, MD

Blood (2013) 122 (21): 3146.

https://doi.org/10.1182/blood.V122.21.3146.3146

Published: 2013

Journal Articles

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 493.

https://doi.org/10.1182/blood.V118.21.493.493

Published: 2011

Journal Articles

Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy.

Anja Mangatter, Stefan O Schoenland, Marion Hansberg, Tilmann Bochtler, Sascha Dietrich, Peter Dreger, Kai Neben, Anthony Ho, Hartmut Goldschmidt, Ute Hegenbart

Blood (2008) 112 (11): 3334.

https://doi.org/10.1182/blood.V112.11.3334.3334

Published: 2008

Journal Articles

Evaluation of Safety and Efficacy of Different Stem Cell Mobilization Regimens in 110 Patients with Light Chain Amyloidosis

Marion Hansberg, Stefan O Schoenland, Anja Mangatter, Sascha Dietrich, Peter Dreger, MD, Kai Neben, Anthony Ho, Hartmut Goldschmidt, Ute Hegenbart

Blood (2008) 112 (11): 3709.

https://doi.org/10.1182/blood.V112.11.3709.3709

Published: 2008

Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert

Blood (2008) 112 (11): 1558.

https://doi.org/10.1182/blood.V112.11.1558.1558

Published: 2008

Journal Articles

Single Center Experience of Lenalidomide/Dexamethasone Treatment in 40 Patients with Light Chain Amyloidosis: High Toxicity in Patients with Severe Impaired Renal and Cardiac Function.

Stefan O Schoenland, Tilmann Bochtler, Sascha Dietrich, Ulrike Klein, Hartmut Goldschmidt, Anthony Ho, Ute Hegenbart

Blood (2008) 112 (11): 1736.

https://doi.org/10.1182/blood.V112.11.1736.1736

Published: 2008

Journal Articles

Increased Aldehyde Dehydrogenase Activity Indentifies a Subset of Human Leukemic Blasts with Stem Cell Characteristics and Correlates with Poor Prognosis.

Dan Ran, Mario Schubert, MD, Larissa Pietsch, Isabel Taubert, Christian Wallenwein, Katrin Miesala, Kerstin Woerner, Patrick Wuchter, MD, Volker Eckstein, PhD, Tom Bruckner, PhD, Anthony Ho, MD

Blood (2008) 112 (11): 1345.

https://doi.org/10.1182/blood.V112.11.1345.1345

Published: 2008

Journal Articles

Chromosomal Instability Correlates with Poor Outcome in Patients with Myelodysplastic Syndromes

Christoph E. Heilig, Harald Löffler, Anna Jauch, Ulrich Mahlknecht, Anthony Ho, Alwin Krämer

Blood (2008) 112 (11): 5077.

https://doi.org/10.1182/blood.V112.11.5077.5077

Published: 2008

Journal Articles

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood (2007) 110 (11): 788.

https://doi.org/10.1182/blood.V110.11.788.788

Published: 2007

Journal Articles

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Volker Diehl, Corinne Brillant, Andreas Engert, Ralf-Peter Mueller, Hans-Theodor Eich, Konrad Mueller-Hermelink, Richard Herrmann, Jana Markova, Anthony Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Josting, Beate Pfistner

Blood (2005) 106 (11): 816.

https://doi.org/10.1182/blood.V106.11.816.816

Published: 2005

Journal Articles

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood (2005) 106 (11): 13.

https://doi.org/10.1182/blood.V106.11.13.13

Published: 2005

Journal Articles

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Timon Seeger, Marlon Veldwijk, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Hartmut Goldschmidt, MD, Anthony Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 1969.

https://doi.org/10.1182/blood.V106.11.1969.1969

Published: 2005

Journal Articles

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma

Carmen Choi, Mathias Witzens, Marianna Bucur, Markus Feuerer, Nora Sommerfeldt, Andreas Trojan, Anthony Ho, Volker Schirrmacher, Hartmut Goldschmidt, Philipp Beckhove

Blood (2005) 105 (5): 2132–2134.

https://doi.org/10.1182/blood-2004-01-0366

Published: 2005

Includes: Supplemental data

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Journal Articles

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Ulrich J.M. Mey, MD, John W. Strehl, MD, Katjana S. Orlopp, MD, Dimitri Flieger, MD, J. Birkmann, MD, Anthony Ho, MD, U. Kaiser, MD, Andreas Neubauer, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 4618.

https://doi.org/10.1182/blood.V104.11.4618.4618

Published: 2004

Journal Articles

Polychemotherapy in patients with primary CNS lymphoma.

Axel Glasmacher, MD, Hendrik Pels, MD, Christoph Helmstaedter, MD, Martina Deckert, MD, Frank Kroschinsky, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Gerlinde Egerer, MD, Anthony Ho, MD, Holger Schulz, MD, Andreas Engert, MD, Volker Diehl, MD, Udo Bode, MD, Thomas Klockgether, MD, Uwe Schlegel, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 3304.

https://doi.org/10.1182/blood.V104.11.3304.3304

Published: 2004

NARROW

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy.

Evaluation of Safety and Efficacy of Different Stem Cell Mobilization Regimens in 110 Patients with Light Chain Amyloidosis

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Single Center Experience of Lenalidomide/Dexamethasone Treatment in 40 Patients with Light Chain Amyloidosis: High Toxicity in Patients with Severe Impaired Renal and Cardiac Function.

Increased Aldehyde Dehydrogenase Activity Indentifies a Subset of Human Leukemic Blasts with Stem Cell Characteristics and Correlates with Poor Prognosis.

Chromosomal Instability Correlates with Poor Outcome in Patients with Myelodysplastic Syndromes

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Polychemotherapy in patients with primary CNS lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only